由于COVID销售下降、专利损失和医疗补助削减,Pfizer削减了2026年利润预测。 Pfizer cuts 2026 profit forecast due to falling COVID sales, patent losses, and Medicaid cuts.

由于COVID-19产品销售下降、专利到期和美国医疗补助定价削减,Pfizer降低了2026年的利润预测,预计调整后的收益为每股2.8美元至3.00美元,低于分析人员预期的3.05美元。 Pfizer lowered its 2026 profit forecast due to declining COVID-19 product sales, patent expirations, and U.S. Medicaid pricing cuts, projecting adjusted earnings of $2.80 to $3.00 per share, below the $3.05 expected by analysts. 预计收入介于595亿至625亿美元之间,略低于预测。 Revenue is expected to range from $59.5 billion to $62.5 billion, slightly below forecasts. 与COVID有关的收入减少15亿美元,丧失的排他性收入再减少15亿美元,将影响结果。 A $1.5 billion drop in COVID-related revenue and another $1.5 billion from lost exclusivity will weigh on results. 该公司预计业务增长4%,不包括受影响的产品,计划到2027年通过削减成本每年节省70多亿美元,并打算到2029-2030年通过收购、新药和研发投资恢复收入增长。 The company expects 4% operational growth excluding affected products, plans to save over $7 billion annually by 2027 through cost cuts, and aims to return to revenue growth by 2029–2030 via acquisitions, new drugs, and R&D investments.